Novo Nordisk (NYSE:NVO) Valuation Check After Mixed Returns And Undervalued Narrative

Simply Wall St.01-24 10:38

AdvertisementWhat Novo Nordisk’s recent performance data tells you Novo Nordisk (NYSE:NVO) has posted mixed return figures, with the share price roughly flat over the past week and slightly higher ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605238615?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-01-24 10:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605238615","market":"hk","top_or_hot":-1,"title":"Novo Nordisk (NYSE:NVO) Valuation Check After Mixed Returns And Undervalued Narrative","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat Novo Nordisk’s recent performance data tells you Novo Nordisk (NYSE:NVO) has posted mixed return figures, with the share price roughly flat over the past week and slightly higher ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nysenvo-valuation-check-after-mixed-returns-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk (NYSE:NVO) Valuation Check After Mixed Returns And Undervalued Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk (NYSE:NVO) Valuation Check After Mixed Returns And Undervalued Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-24 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nysenvo-valuation-check-after-mixed-returns-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat Novo Nordisk’s recent performance data tells you Novo Nordisk (NYSE:NVO) has posted mixed return figures, with the share price roughly flat over the past week and slightly higher ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nysenvo-valuation-check-after-mixed-returns-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nysenvo-valuation-check-after-mixed-returns-and","article_id":"2605238615","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nysenvo-valuation-check-after-mixed-returns-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605238615","pubTimestamp":1769222317,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What Novo Nordisk’s recent performance data tells you\nNovo Nordisk (NYSE:NVO) has posted mixed return figures, with the share price roughly flat over the past week and slightly higher over the past day, while showing stronger gains over the past month and past 3 months.\nAt the same time, longer term data is uneven, with a negative 1 year total return and a modest negative 3 year total return, set against a very large 5 year total return that points to a materially different outcome for...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4007":"制药","NVO":"诺和诺德","BK4588":"碎股","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD"},"translate_title":"诺和诺德（纽约证券交易所股票代码：NVO）在混合回报和低估叙述后进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.98},"content_text":"AdvertisementWhat Novo Nordisk’s recent performance data tells you Novo Nordisk (NYSE:NVO) has posted mixed return figures, with the share price roughly flat over the past week and slightly higher over the past day, while showing stronger gains over the past month and past 3 months. At the same time, longer term data is uneven, with a negative 1 year total return and a modest negative 3 year total return, set against a very large 5 year total return that points to a materially different outcome for earlier investors. See our latest analysis for Novo Nordisk. For Novo Nordisk, the recent 18.5% 1 month share price return and 17.6% 3 month share price return contrast sharply with a 27.8% 1 year total shareholder return decline, suggesting momentum has picked up after a tough year. If this kind of rebound has you thinking about where else growth or recovery stories might be taking shape, it could be a good time to scan healthcare stocks. With Novo Nordisk trading close to analyst targets but showing a large intrinsic discount score, it raises a key question for you: is the market underestimating the business or already banking on future growth? Most Popular Narrative: 34.5% Undervalued According to the most followed narrative on Novo Nordisk, a fair value of $95 per share sits well above the last close at $62.26, which frames the current share price as a sizeable discount to that estimate.  Novo Nordisk, a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05, reflecting a normalized P/E ratio of just 13.4×, down from a five-year average closer to 25 to 30×.  Read the complete narrative. Want to see what sits behind that $95 figure? The narrative leans on consistent profit growth, resilient margins, and a future earnings multiple usually reserved for market favorites. Curious which specific assumptions drive that gap to today’s price? Result: Fair Value of $95 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to watch for competitive pressure in obesity drugs and policy driven pricing changes that could put this 34.5% undervalued view under strain. Find out about the key risks to this Novo Nordisk narrative.  Build Your Own Novo Nordisk Narrative If you see this differently or prefer to test the assumptions yourself, you can build your own view in just a few minutes with Do it your way. A great starting point for your Novo Nordisk research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision. Looking for more investment ideas? If you are serious about broadening your watchlist, this is the moment to look beyond a single stock and see what else might fit your plan.  Spot potential value gaps by checking out these 864 undervalued stocks based on cash flows that may trade below what their cash flows suggest. Explore the growth of machine learning and automation by scanning these 24 AI penny stocks that could influence how businesses use data. Add income focused names to your radar with these 13 dividend stocks with yields > 3% offering yields above 3% that might suit a cash flow oriented portfolio.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Novo Nordisk might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605238615","isCrawlerRequest":true}